GLP-1 RAs, originally developed for glycemic control in type 2 diabetes, have demonstrated mechanistic plausibility and emerging clinical efficacy in modulating key pathophysiological processes implicated in depression, including insulin resistance, neuroinflammation, and reward system dysregulation. Here, GLP1R is linked to depressive symptom measurement.